For research use only. Not for therapeutic Use.
Tisotumab vedotin（Cat No.:I041181）is an antibody-drug conjugate (ADC) designed to target and treat solid tumors, particularly those expressing the tissue factor (TF) protein, commonly found in various cancers like cervical and ovarian cancers. It combines an anti-TF monoclonal antibody with the cytotoxic agent MMAE (monomethyl auristatin E), which is delivered directly to cancer cells upon binding. This targeted delivery enhances the effectiveness of chemotherapy while minimizing damage to healthy tissue. Clinical trials are ongoing to assess its safety, efficacy, and potential as a treatment for TF-positive cancers, including those resistant to traditional therapies.
| CAS Number | 1418731-10-8 |
| Purity | ≥95% |
